CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT
The clinical study of CART19 Cells treatment for MRD of B Cell Malignancies and then auto-HSCT
Leukemia, Lymphocytic, Acute, B-Cell|Leukemia, Lymphocytic, Chronic, B-Cell|Lymphoma, B-Cell
BIOLOGICAL: CART19 cell and auto-HSCT
CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT, The incidence of conversion of minimal residual disease (MRD) to \<0.01% after CART19 therapy in patients with MRD of B Cell Malignancies during upfront treatment, day 28
The clinical study of the chimeric antigen receptor T cells (CART Cells) treatment for minimal residual disease(MRD) of B Cell Malignancies and then autologous hematopoietic stem cell transplantation(auto-HSCT).